Study [references]

 

Stage

Radiation
techniques

Chemotherapy

Sample size
(n)

Follow up period
(months)

Disease Free Survival

Overall survival

Grade 3 Acute  toxicity
incidence

Grade 3 Late
toxicity

 

Lupe K, et al. [10]

 

FIGO
IIIA-IVA

 

Pelvic RT 45 Gy ± para-aortic RT and VBT

 

Adjuvant Paclitaxel+ carboplatin x 4 before RT

 

63

 

24

 

55%

 

55%

 

12%

 

18%

 

Alvarez Secord A, et al. [11]

 

Retrospective
FIGO
IIIA- IVA

 

Pelvic RT 45 Gy ± para-aortic RT and VBT

 

NA

 

83

 

36

 

62%

 

79%

 

NA

 

NA

 

Geller MA, et al. [12]

 

FIGO III-IVA

 

Pelvic RT 45 Gy ±  VBT

 

Docetaxel+ carboplatin C4→RT → Docetaxel+ carboplatin x C2

 

42

 

28

 

71%

 

90%

 

54%

 

NA

 

Secord AA, et al. [13]

 

FIGO III-IVA

 

Pelvic RT 45 Gy ±  VBT

 

Three arms:

  1. C→RT→C
  2.       RT→C
  3.       C→RT

 

  1. 45
  2. 18
  3. 46

 

36

 

  1. 69%
  2. 47%
  3. 52%

 

  1. 88%
  2. 54%
  3. 57%

 

NA

 

NA

 

Fields AL, et al. [14]

 

Papillary serous carcinoma

 

Pelvic RT 45 Gy ± para-aortic RT

 

Adjuvant Paclitaxel+ carboplatin x C4 before RT

 

30

 

36

 

54-69%

 

52-75%

 

43%

 

NA

 

Present study

 

FIGO IA-IIB

 

Pelvic RT 45 Gy +VBT 15 Gy

 

Two arms

  1. RT alone
  2. Adjuvant   Paclitaxel+

        Carboplatin x
        C4 before RT    

 

56

 

55

 

78.6%

 

81.9%

 

9.5%

 

1.7%
FIGO= International Federation of Gynecology and Obstetrics, RT= radiation therapy, VBT= vaginal brachytherapy, NA= not available, xC= cycles, C= chemotherapy
Table 5: Comparison of various studies using sequential chemotherapy and radiotherapy and its impact on treatment outcomes.